Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib may effectively treat folliculitis decalvans.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Azathioprine can cause severe hair loss and low white blood cell count in lupus patients.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.

Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

PLD is an effective and safer alternative for treating breast cancer.

Upadacitinib effectively treats severe alopecia areata and is safe.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.